Can Fite Biopharma Ltd ADR CANF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027
Can-Fite's Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study: Published in Nature Portfolio Journal
Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study
Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones
Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Trading Information
- Previous Close Price
- $1.47
- Day Range
- $1.42–1.47
- 52-Week Range
- $1.42–10.39
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 3.03M
- Market Cap
- $4.35M
- Volume/Avg
- 16,827 / 364,824
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.52
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.canfite.com
Valuation
Metric | CANF |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.63 |
Price/Sales | 5.52 |
Price/Cash Flow | — |
Price/Earnings
CANF
Financial Strength
Metric | CANF |
|---|---|
Quick Ratio | 3.17 |
Current Ratio | 3.60 |
Interest Coverage | — |
Quick Ratio
CANF
Profitability
Metric | CANF |
|---|---|
Return on Assets (Normalized) | −110.70% |
Return on Equity (Normalized) | −191.35% |
Return on Invested Capital (Normalized) | −195.53% |
Return on Assets
CANF
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|<kftLG | LOCK|^W?&$ | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|^%xn%c% | LOCK|#@Bp | $95B | |||
| Moderna Inc MRNA | LOCK|NmDyMNd | LOCK|$p% | $79B | |||
| argenx SE ADR ARGX | LOCK|K&^<!d | LOCK|tpk | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|T!$Bcl | LOCK|&mk | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|!&VXHJpk | LOCK|t>pM | $30B | |||
| Incyte Corp INCY | LOCK|QKsmM$ | LOCK|<M | $23B | |||
| BioNTech SE ADR BNTX | LOCK|M%??&^ | LOCK|$h | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|JSH^zG@ | LOCK|#j@% | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|$t@!N> | LOCK|<<@ | $15B |